Core Viewpoint - Biodexa Pharmaceuticals Plc is under investigation for potential claims related to its securities following the release of concerning clinical trial data for its drug MX110, which has led to a significant drop in its stock price [1][2]. Investigation Details - On October 4, 2024, Biodexa reported updated data from a Phase 1 study of MX110 for recurrent glioblastoma, revealing that out of four patients in Cohort A, two have died, with overall survival times of 12 and 13 months for the remaining patients [2]. - Following this announcement, Biodexa's stock price decreased by 5.55 per share on the same day [2]. Next Steps - Investors who have information related to the investigation or who purchased Biodexa securities are encouraged to assist by visiting the law firm's website [3]. Legal Representation - Bronstein, Gewirtz & Grossman, LLC operates on a contingency fee basis, meaning they will only seek reimbursement for expenses and attorney fees if they are successful in the case [4]. Firm Background - Bronstein, Gewirtz & Grossman, LLC is a recognized firm specializing in representing investors in securities fraud class actions and has successfully recovered hundreds of millions of dollars for investors [5].
BDRX INVESTOR ALERT: Bronstein, Gewirtz and Grossman, LLC Announces an Investigation into Biodexa Pharmaceuticals Plc and Encourages Investors to Contact the Firm